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Abstract 
Heparin is commonly used for prevention or treatment of cancer-associated 
thromboembolism. Recent clinical evidence indicates that heparin, and low-molecular weight 
heparin improves survival of cancer patients. Experimental evidence from various animal 
models consistently supports the ability of heparin to attenuate metastasis. Heparin, apart 
from its anticoagulant activity contains a variety of biological activities possibly affecting 
cancer progression, including: inhibition of heparanase, blocking of P- and L-selectin 
mediated cell adhesion, and inhibition of angiogenesis. The delineation of antimetastatic 
activity of heparin is in the focus of several ongoing investigations. This review summarizes 
the current experimental evidence on the biology of heparin as a potential treatment cancer 
progression.  
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Introduction 
Cancer-associated thrombosis is a frequent complication associated with cancer progression 
[1]. Heparin and low molecular weight heparin (LMWH) are commonly used for the 
prevention or treatment of thromboembolic complications in cancer patients [2, 3]. Based on 
earlier observations linking the anticoagulant therapy with heparin to an improved survival of 
cancer patients, several prospective clinical trial were launched with the aim to test heparin as 
a potential anticancer treatment (see reviews [4-6]. Preclinical analysis of heparin provides 
evidence for its antimetastatic activity in a variety of animal models (see reviews [7, 8]. While 
the potential of heparin to attenuate metastasis in experimental models is well accepted, the 
underlying molecular mechanism of heparin action in this process is a topic of ongoing 
investigations. 
Heparin is a complex mixture of natural glycosaminoglycans purified from porcine intestine 
[9]. These linear polymers are composed of a repetitive disaccharide unit containing a 
glucosamine residue and glucuronic/iduronic acid [10]. Both units are sulfated and the degree 
of sulfation of the disaccharide units varies throughout the polymer. Clinical preparation of 
heparin is a polydisperse mixture of glycosaminoglycans that is adjusted for the anticoagulant 
activity [9]. However, only a small portion of the heparin preparation actually contains the 
anticoagulant activity. The binding site of heparin to antithrombin III has been identified as a 
specifically sulfated pentasaccharide sequence [9]. In addition, multiple subsets of heparin 
chains were shown to interact with a large number of other molecules including enzymes (e.g. 
heparanase), cell adhesion molecules (e.g. P- and L-selectin), growth factors and cytokines [9, 
11-13]. Specific targeting of any of these biological activities by heparin or LMWH was 
shown to affect the biology of cancer in certain models. Nevertheless, an identification of the 
critical biological activity of heparin responsible for the attenuation of metastasis was proven 
difficult due to the very nature of heparin that is represented by a mixture of 
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glycosaminoglycans carrying partially overlapping biologically active sites. Nevertheless, the 
recent use of modified heparins with a characterized “narrower” biological activity in vivo 
points toward the critical role of heparin during metastasis [14-19].  
 
Heparin attenuates metastasis in animal models 
Heparin and LMWH were tested in many different animal models for their potential cancer 
inhibiting activity. Heparins were repeatedly shown to effect cancer progression, while their 
effect on tumor growth was rather limited [16, 20, 21]. Over the last twenty years, the 
antimetastatic activity of heparins was primarily observed in animal models of experimental 
metastasis (Table 1). An overview of studies prior to this period is excellently reviewed 
elsewhere [7, 8]. The experimental metastasis model does not completely recapitulate the 
natural process of metastatic spread, thus very early steps of local tumor cell dissemination 
and intravasation needs to be analyzed in spontaneous metastasis models. Despite many 
limitations of this experimental approach, the timely defined presence of tumor cells in 
circulation allows the evaluation of cellular and molecular mechanisms during the 
hematogenous phase of metastasis. Accordingly the biological effect of heparin during this 
process can be assessed. A variety of heparin preparations, including unfractionated heparin, 
LMW heparin and several chemically modified heparins with a reduced or a minimal 
anticoagulant activity, efficiently reduced metastasis when applied shortly before or after the 
tail vein injection of tumor cells (Table 1). When heparin was applied twenty four hours 
before or after the tumor cell injection no effect was observed [22, 23]. Only in one study 
heparin treatment one day before the tumor cell injection and daily during the first three days 
form tumor cell injection was reported to attenuate metastasis [24]. However, the attenuation 
of metastasis in this study may be affected largely by the heparin application at the time of 
tumor cell injection that was not specified [24]. In general, attenuation of metastasis was 
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independent of the route of heparin application. Intravenous application of heparin around the 
time of tumor cell injection always led to reduction of metastasis. Subcutaneous or 
intraperitoneal application of heparin around the time of tumor cell injection led mostly to 
attenuation of metastasis [11, 14, 20, 25-27], while in some studies the affectivity of heparin 
was limited [17, 28-30]. Attenuation of metastasis was repeatedly observed in most of the 
studies despite a wide range of heparin dosages applied (Table 1). In most studies, the amount 
of heparin applied exceeded the therapeutic dose used in humans. Recently, the efficacy of 
heparin to inhibit metastasis was also documented at clinically relevant concentrations [26, 
31]. In studies with a limited effect of heparin on metastasis [28], the applied heparin dosage 
was comparable to studies where attenuation of metastasis was detected (e.g. [25]. However, 
the limited response to heparin treatment was likely due to differences in time and/or route of 
heparin application, different amount of heparin applied and possible variation in heparin 
preparations [17, 28, 29, Niers, 2009 #2178]. Clinically used heparin preparations are adjusted 
according to their anticoagulant acitivity. Accordingly, different heparin formulations are not 
necessarily identical in “other” biological activities responsible for the antimetastatic effect of 
heparin.  
 
Potential mechanisms for heparin affects on metastasis 
Hematogenous metastasis consist of a multistep process in which tumor cells enter the blood 
circulation, evade immune responses, adhere to the endothelium of distant organs, extravasate 
and colonize the tissue [32, 33]. The common observation that a single injection of heparin, at 
the time when tumor cells are still in circulation, attenuates metastasis indicates that inhibition 
of cellular events during the hematogenous phase profoundly affect this process. This 
conclusion is further supported by the fact, that the half-life of heparin in blood circulation is 
relatively short and last for four to six hours [14, 34]. Thus it is unlikely that heparin exerts its 
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antimetastatic activity through inhibition of angiogenesis that would require a prolonged 
heparin treatment. Therefore, the antimetastatic activities of heparins were analyzed for their 
potential to: affect anticoagulation; inhibit heparanase and to block P- and L-selectin in 
particular. 
 
Anticoagulant activity and metastasis  
Unfractionated heparin and LMWH has been in clinical use for decades as an effective 
inhibitor of fluid phase coagulation by enhancing antithrombin inactivation of factors IIa and 
Xa. Intravenous injection of tumor cells leads to tumor cell emboli formation resulting in the 
tumor cell entrapment in the pulmonary vasculature [34-36]. Tumor cell associated activation 
of the coagulation cascade, often expressed by tumor cells, results in a rapid fibrin deposition 
detected both by intravascular tumor cells and in the metastatic lesions [36, 37]. Some 
experimental studies have demonstrated that anticoagulation using antithrombin inhibitor 
hirudin attenuated metastasis [36, 38]. However, the dose of hirudin used led to an excessive 
anticoagulation affect that is not compatible with the clinical use. Conversely, a continuous 
treatment with an oral thrombin inhibitor led to an accelerated pulmonary metastasis [39]. 
Another anti-metastatic property of heparin, with respect to anticoagulation, is related to the 
capacity of heparin to release tissue factor pathway inhibitor (TFPI) from vascular 
endothelium thereby contributing to the antiangiogenic activity of the TF inhibitor [40-42]. 
The use of non-anticoagulant heparin derivatives in a number of animal models resulted in 
attenuation of metastasis, further demonstrating that the antimetastatic activity of heparins is 
independent of anticoagulation [14, 16, 17, 28, 43, 44]. The pentasaccharide fondaparinux, an 
excellent anticoagulant that potentiates antithrombin III, had no affect on metastasis at 
clinically tolerable levels [26, 31]. 
 
Heparanase activity 
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Tumor cell invasion is a critical step in the metastatic cascade. The invasiveness of tumor 
cells is associated with the capacity to degrade extracellular matrix components by producing 
hydrolytic enzymes such as matrix metalloproteinases or heparanase. Elevated levels of 
heparanase were associated with cancer progression and poor prognosis in various carcinomas 
of colon, liver, breast, bladder and also multiple myeloma [45]. Heparanase activity correlated 
with the metastatic potential of B16 mouse melanoma and Eb lymphoma cells [46, 47]. 
Heparin treatment inhibited heparanase activity and led to attenuation of metastasis [47, 48]. 
In a myeloma cell model, enhanced expression of heparanase was shown to induce metastasis 
[49]. Heparanase expression in myeloma was associated with an enhanced shedding of 
syndecan-1 and correlated with poor prognosis [50, 51]. Silencing of the heparanase gene led 
to marked reduction of heparanase enzymatic activity in B16 melanomas that resulted in 
reduced lung colonization [52]. Heparin derivatives characterized by their ability to inhibit 
heparanase were evaluated for their anti-metastatic activity in a number of animal models [11, 
12, 22]. Since the antimetastatic activity of heparins may be caused by other biological 
activities, like inhibition cell-cell interaction mediated by P- and L-selectin, heparins were 
tested for both activities in parallel [14]. P-selectin specific heparin derivatives reduced 
metastasis of tumor cells regardless of heparanase expression. Heparin derivatives with 
specific heparanase inhibitory activity reduced the metastatic capacity of tumor cells (e.g. B16 
melanoma cells) expressing this enzyme, while showing no affect with tumors without 
heparanase expression (MC-38 carcinoma cells). These results indicate that inhibition of 
selectins by heparin probably precedes the heparanase inhibitory activity as observed in the 
experimental metastasis model. 
 
Selectin as mediators of metastasis 
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During hematogenous metastasis tumor cells in a blood circulation has to survive and adhere 
to the vasculature in the target organs. Enhanced platelets-tumor cell emboli formation 
correlated with metastatic progression [53-55]. Tumor cells covered with platelet aggregates 
were shown to evade immune responses in the blood circulation [56]. Thus, cell-cell 
interactions of tumor cell within the vascular environment are critical for metastatic 
progression. Selectins represent the major group of cell adhesion molecules that were linked 
to hematogenous metastasis. Selectins are vascular cell adhesion molecules that mediate the 
initial steps of leukocytes and platelets interactions with the endothelial cells under normal 
physiological condition [57]. While activation of platelets and endothelial cells lead to a rapid 
cell surface expression of P-selectin, virtually all populations of leukocytes constitutively 
express L-selectin. E-selectin expression on the cell surface of endothelial cell is induced by a 
prolonged activation. In addition to their physiological function, selectin were shown to 
contribute to metastasis by mediation of cell interaction among tumor cells, platelets, 
leukocytes and endothelial cells [23, 34, 37, 58-60]. The absence of P-selectin led to 
attenuation of experimental metastasis in several animal models [23, 58, 59]. A marked 
reduction of platelet-tumor cell thrombi formation in P-selecitn deficient mice was found to 
be responsible for attenuation of metastasis [34, 58]. An experimental elimination of 
circulating platelets resulted in reduced metastasis [55], further supporting the role of platelets 
in this process. Collectively, these observations strongly indicate the pivotal role of P-selectin 
in facilitation of metastasis through mediation of platelet-tumor cell interactions. In addition, 
endothelial expression of P-selectin was also reported to enhance metastasis [23]. The bone 
marrow rescue of lethally irradiated P-selectin deficient mice with the wild type bone marrow 
led to a marked reduction of metastasis. This observation indicates that early endothelial 
activation, thereby P-selectin expression on vasculature, contributes to metastasis in these 
chimeric mice where P-selectin is present on platelets only.  E-selectin expression has been 
also studied for its potential to mediate metastasis. Transgenic overexpression of E-selectin in 
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the liver increased metastasis to this tissue, indicating the involvement of E-selectin in liver 
metastasis [60]. In the absence of L-selectin significant attenuation of metastasis was 
observed in two different mouse models, thus actively implicating leukocytes in facilitation of 
metastasis [59]. Even a transient inhibition of L-selectin during the intravascular phase of 
tumor cells led to attenuation of metastasis to the comparable levels as observed in L-selectin 
deficient mice [37]. Further characterization of leukocytes suggested that myeloid-derived 
leukocytes through L-selectin mediated interactions mediate the initial steps of metastasis.  
Selectins bind to specific glycan structures, which are presented on the cell surfaces of many 
tumor cells. Virtually all carcinomas express selectin ligands due to an abundant expression of 
mucins. Carcinoma mucins are carriers of O-glycan structures, including the expression of 
sialyl Lewis x (sLex) that serves as the core component of a selectin ligand [61]. The positive 
correlation between sLex expression and poor prognosis was observed in gastric, colon, lung, 
prostate and breast cancers [62-66]. The presence of carcinoma cells, carrying selectin 
ligands, in the blood circulation together with the presence vascular selectins makes them the 
potential mediators of cell interactions leading to metastasis. 
 
Heparin reduces metastasis through inhibition of selectins  
Heparin has a variety of biological activities, including the capacity to effectively inhibit P-
and L-selectins despite no similarity to natural selectin ligands [13, 67]. The hypothesis that 
selectins mediate metastasis was explored by a number of laboratories, and the recent 
evidence confirmed the contribution of P-and L-selectin to metastasis [23, 34, 37]. To address 
the heparin activity during metastasis, P- and/or L-selectin deficient mice were injected with 
unfractionated heparin shortly before intravascular injection of either carcinoma or melanoma 
cells [23, 34, 37, 59]. A single bolus injection of heparin attenuated metastasis in wild type 
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mice to a similar level as observed in P-selectin deficient mice [23, 34]. Furthermore, single 
heparin injection in P-selectin deficient mice had no further effect on metastasis [34]. 
Interestingly, single dose of heparin prior to tumor cell injection further attenuated metastasis 
in L-selectin deficient mice, indicating that L-selectin involvement in this process is 
subsequent to P-selectin involvement [59]. This hypothesis was confirmed in another study, 
where L-selectin mediated recruitment to metastasis cells was observed 9 to12 hours after 
tumor cell injection [37]. When heparin was applied six hours after tumor cell injection 
further attenuation of metastasis was observed in P-selectin deficient mice. Conversely, the 
application of heparin six hours after tumor cell injections had no further effect on metastasis 
in L-selectin deficient mice [37]. When heparin was applied either shortly before or six hours 
after tumor cell injection no further effect on metastasis in P- and L-selectin double deficient 
mice was observed [59, 68]. Interestingly, repeated injection of high doses of unfractionated 
heparin led to a prolonged survival of mice, indicating that heparin at such doses might have 
further antimetastatic activities to selectin inhibition [68]. Finally, extensive characterization 
of modified non-anticoagulant heparins led to identification of a particular heparin derivative 
(58% N-acetylated heparin), that contains excellent P-selectin inhibitory activity while 
preserving minimal heparanase inhibitory activity and reduced growth factor binding activity 
[14]. This heparin derivative reduced metastasis of mouse colon carcinoma and melanoma 
cells. Collectively, these findings strongly suggest that heparin inhibits metastasis by 
interference with P-and L-selectin mediated cell-cell interactions. While the contribution of P-
selectin to metastasis is partially characterized, the consequence of L-selectin involvement, 
thereby leukocytes, remains to be further analyzed.   
 
Heparin attenuates metastasis. Published evidence versus a mechanism of action 
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Hematogenous metastasis is directly or indirectly responsible for most cancer-related deaths. 
A summary of experimental evidence on heparin treatment of various cancer cells using a 
broad range of heparin doses as well as different heparin preparations and derivatives is 
presented in Table 1. Attenuation of metastasis has been observed when: 1) heparin was 
applied around the time of intravenous tumor cell injection; 2) the amount of heparin applied 
was at least at the clinically used concentrations. Only in two studies had heparin treatment no 
affect on metastasis when applied either one hour after tumor cell injection [29] or one hour 
before injection [17]. In most of the studies, heparin doses were several times higher than 
clinically used doses in humans. Considering the higher sensitivity of human P-selectin to 
heparin inhibition when compared to mouse P-selectin (about 10 fold difference), these 
findings suggest even better responses to be expected in humans, assuming that P-selectin is 
one of the primary targets during metastasis [69]. The affectivity of non-anticoagulant 
heparins to attenuate metastasis clearly separates the anticoagulant activity of heparin from its 
antimetastatic activity. Considering the transient presence of heparin in blood circulation that 
usually last for several hours [34], the possible biological activity of heparin on angiogenesis, 
tumor cell growth and invasiveness mediated by heparanase are rather limited.  The 
accumulated evidence on the anti-metastatic activity of heparin over the large number of 
studies is compatible with the described role of P- and L-selectin mediated interactions during 
hematogenous metastasis. Further characterizations of heparins will provide additional 
insights into the precise mechanism of heparin action during metastasis. However, it might 
well be that “the sum” of biological activities defined by the very nature of heparin molecules 
will be the right treatment of cancer progression affecting not only selectins or heparanase, 
but also a number of other mechanisms potentially critical in a different cancers. Finally, the 
available evidence from clinical trials [4] strongly supports the future evaluation of heparin as 
a potential anti-metastatic treatment. 
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Table 1 
Effect of heparins on experimentally induced lung metastasis after the intravenous injection of cancer cells 
 
Tumor type Heparin dose a Doses schedule b Effect on Metastasis Reference 
     
M mammary carcinoma UFH 40 IU/mouse  - 24 h and - 1 h  i.p. Decrease Lee et al. [27] 
M mammary carcinoma UFH 40 IU/kg  -24 h and - 1 h i.p. Decrease Lee et al. [20] 
M melanoma UFH 0.4 mg/mouse  - 20 min i.v. Decrease Vlodavsky et al. [22] 
   - 1 day i.v. No effect  
 LMWH 0.4 mg/mouse  - 20 min i.v. Decrease  
   - 1 day i.v. No effect  
M melanoma UFH modified 10 mg/kg  - 10 min & twice a week i.v. Decrease Sciumbata et al. [21] 
M melanoma UFH modified 50 mg/kg  - 1 h  & once daily for 3 days s.q. Decrease Lapierre et al. [28] 
 UFH modified 10 mg/kg  - 1 h  & once daily for 3 days s.q. No effect  
M melanoma LMWH 100 μg/mouse  - 20 min  i.v. Decrease Miao et al. [11] 
R mammary carcinoma LMWH 3.6 mg/rat  - 20 min  i.p. Decrease  
H colon carcinoma UFH 100 IU/mouse  - 30 min i.v. Decrease Borsig et al. [34] 
M colon carcinoma UFH 100 IU/mouse  - 30 min i.v. Decrease Borsig et al. [59] 
M melanoma UFH and UFH modified  0.2-0.5 mg/mouse Coinjected i.v. Decrease Poggi et al. [70] 
 UFH and UFH modified 0.1-0.5 mg/mouse  - 1 h  i.v. Decrease  
M melanoma LAC H or LMWH 1.0 mg/mouse once daily for 7 days i.v. Decrease Ono et al. [44] 
M lung carcinoma LAC H or LMWH 1.0 mg/mouse once daily for 7 days i.v. Decrease  
M melanoma LMWH 10 mg/kg  - 4 h s.q. Decrease Amirkhosravi et al. [25]  
M melanoma UFH 12.5 or 60 IU/mouse  - 30 min route not specified Decrease Ludwig et al. [23] 
 UFH 60 IU/mouse  + 24 h and then every second day No effect  
M lung carcinoma LAC H 0.5-2.0 mg/mouse  - 10 min i.v. Decrease Yoshitomi et al [17] 
 LAC H 1 mg/mouse  - 1 h s.q. No effect  
M melanoma LAC H 1 mg/mouse  - 10 min i.v. Decrease  
M colon carcinoma LAC H 1 mg/mouse  - 10 min i.v. Decrease  
M osteosarcoma  LAC H 1 mg/mouse  - 10 min i.v. Decrease  
M colon carcinoma UFH 6.6 IU/mouse  - 30 min s.q. Decrease Stevenson et al. [26] 
 LMWH 7.3 IU/mouse  - 30 min s.q. Decrease  
M melanoma UFH 6.6 IU/mouse  - 30 min s.q. Decrease  
 LMWH 7.3 IU/mouse  - 30 min s.q. Decrease  
M melanoma NAC H 50 mg/kg  - 4 h s.q. Decrease Kragh et al. [16] 
H melanoma UFH and LMWH 200 IU/kg  - 1 day & once daily for 3 days i.p. Decrease Bereczky et al. [24] 
M lung carcinoma UFH 100 IU/mouse  + 1 h  s.q. No effect Szende et al. [29] 
 LMWH 38 IU/mouse  + 1 h  s.q. No effect  
 LMWH 57 IU/mouse  + 1 h  s.q. Decrease  
M colon carcinoma UFH 100 IU/mouse  + 6 h and + 12 h  i.v. Decrease Laubli et al. [37] 
M melanoma LMWH and NAC LMWH 200 μg/mouse  - 4 h s.q. Decrease Mousa et al. [18] 
M melanoma UFH 10-60 IU/mouse  - 30 min  i.v. Decrease Ludwig et al. [31] 
 LMWH 60 IU/mouse  - 30 min  i.v. Decrease  
M melanoma UFH 0.5-5 mg/kg   - 20 min i.v. Decrease Park et al. [19] 
 UFH modified 0.5-5 mg/kg  - 20 min i.v. Decrease  
M squamous cell carcinoma UFH 0.5-5 mg/kg   - 20 min i.v. Decrease  
 UFH modified 0.5-5 mg/kg  - 20 min i.v. Decrease  
H breast carcinoma UFH 3.3 mg/kg  - 4 h & twice daily  s.q. Decrease Mellor et al. [71] 
H breast carcinoma LMWH 175 IU/kg  - 4 h & once daily  s.q. Decrease Harvey et al. [72] 
 LMWH 90 IU/kg  - 4 h & once daily for 4 days  s.q. Decrease  
M colon carcinoma UFH modified 150 μg/mouse  - 10 min i.v. Decrease Hostettler et al. [14] 
M melanoma UFH modified 150 μg/mouse  - 10 min i.v. Decrease  
 UFH modified 300 μg/mouse  - 30 min s.q. Decrease  
M melanoma LMWH modified 1-10 mg/kg  - 20 min & once daily orally  Decrease Lee et al. [73] 
 LMWH modified 1 mg/kg  - 20 min i.v. & once daily orally Decrease  
H lung carcinoma  LMWH modified 10 mg/kg  - 20 min & once daily orally Decrease  
M  melanoma UFH  15-25 USP/mouse  - 30 min s.q. Decrease Yee et al. [74] 
M melanoma LMWH 600IU/kg prior to tumor cell injection i.p.  No effect Niers et al. [30] 
M melanoma NAC LMWH 10mg/kg  - 10 min route not specified Decrease Niers et al. [39] 
M melanoma UFH and UFH modified 5 mg/kg  - 30 min route not specified Decrease Zhang et al. [75] 
a UFH modified is specifically desulfated; LAC – low anticoagulant, obtained by chemical modification of the heparin; NAC – non-anti-coagulant. 
b Timing of the heparin administration is given in reference to injection of tumor cells. A negative value refers to heparin injection prior to tumor cell administration. 
Route of heparin administration: i.v. = intravenous; s.q. = subcutaneous; i.p. = intraperitoneal.  
M = mouse, H = human, R = rat 
 
